Neuroimaging in Parkinson's disease: from pathology to diagnosis

Vaillancourt, 2009, High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease, Neurology, 72, 1378, 10.1212/01.wnl.0000340982.01727.6e Peran, 2010, Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature, Brain, 133, 3423, 10.1093/brain/awq212 Takeda, 2010, Functional imaging studies of hyposmia in Parkinson's disease, J Neurol Sci, 289, 36, 10.1016/j.jns.2009.08.041 Bohnen, 2010, Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease, Brain, 133, 1747, 10.1093/brain/awq079 Boileau, 2008, Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB, Mov Disord, 23, 1776, 10.1002/mds.22212 Albin, 2008, Spared caudal brainstem SERT binding in early Parkinson's disease, J Cereb Blood Flow Metab, 28, 441, 10.1038/sj.jcbfm.9600599 Albin, 2000, Decreased striatal dopaminergic innervation in REM sleep behavior disorder, Neurology, 55, 1410, 10.1212/WNL.55.9.1410 Iranzo, 2011, Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study, Lancet Neurol, 10, 797, 10.1016/S1474-4422(11)70152-1 Unger, 2010, Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions, Sleep, 33, 767, 10.1093/sleep/33.6.767 Kashihara, 2010, Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson's disease, Parkinsonism Relat Disord, 16, 252, 10.1016/j.parkreldis.2009.12.010 Goldstein DS, Holmes C, Sewell L, Park MY, Sharabi Y. Sympathetic noradrenergic before striatal dopaminergic denervation: relevance to Braak staging of synucleinopathy. Clin Auton Res 2011 Jul 28. Antonini, 1997, Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease, Brain, 120, 2187, 10.1093/brain/120.12.2187 Yoshita, 1998, Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy, J Neurol Sci, 155, 60, 10.1016/S0022-510X(97)00278-5 Ma, 2010, Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI, J Cereb Blood Flow Metab, 30, 505, 10.1038/jcbfm.2009.256 Tang, 2010, Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis, Lancet Neurol, 9, 149, 10.1016/S1474-4422(10)70002-8 Sossi, 2010, Dopamine turnover increases in asymptomatic LRRK2 mutations carriers, Mov Disord, 25, 2717, 10.1002/mds.23356 Khan, 2005, Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation, Neurology, 64, 134, 10.1212/01.WNL.0000148725.48740.6D Khan, 2002, Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study, Ann Neurol, 52, 849, 10.1002/ana.10417 Vingerhoets, 1997, Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?, Ann Neurol, 41, 58, 10.1002/ana.410410111 Doder, 2003, Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study, Neurology, 60, 601, 10.1212/01.WNL.0000031424.51127.2B Nandhagopal, 2009, Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study, Brain, 132, 2970, 10.1093/brain/awp209 de la Fuente-Fernandez, 2011, Age-specific progression of nigrostriatal dysfunction in Parkinson's disease, Ann Neurol, 69, 803, 10.1002/ana.22284 Huang, 2007, Changes in network activity with the progression of Parkinson's disease, Brain, 130, 1834, 10.1093/brain/awm086 Zhan W, Kang GA, Glass GA, Zhang Y, Shirley C, Millin R, et al. Regional alterations of brain microstructure in parkinson's disease using diffusion tensor imaging. Mov Disord 2011 Aug 17. Martin, 2008, Midbrain iron content in early Parkinson disease: a potential biomarker of disease status, Neurology, 70, 1411, 10.1212/01.wnl.0000286384.31050.b5 Gerhard, 2006, In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease, Neurobiol Dis, 21, 404, 10.1016/j.nbd.2005.08.002 Ouchi, 2005, Microglial activation and dopamine terminal loss in early Parkinson's disease, Ann Neurol, 57, 168, 10.1002/ana.20338 Miyoshi, 2010, In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study, Parkinsonism Relat Disord, 16, 404, 10.1016/j.parkreldis.2010.04.004 Bohnen, 2009, History of falls in Parkinson disease is associated with reduced cholinergic activity, Neurology, 73, 1670, 10.1212/WNL.0b013e3181c1ded6 Maetzler, 2009, Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics, Neurobiol Dis, 34, 107, 10.1016/j.nbd.2008.12.008 Jokinen, 2010, [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia, Parkinsonism Relat Disord, 16, 666, 10.1016/j.parkreldis.2010.08.021 Claassen, 2011, Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy, Parkinsonism Relat Disord, 17, 160, 10.1016/j.parkreldis.2010.12.006